Intellia Therapeutics (NTLA) EVP, General Counsel reports RSU sell-to-cover trade

Rhea-AI Filing Summary

Intellia Therapeutics executive James Basta reported a tax-related stock sale. On January 5, 2026, he sold 10,397 shares of Intellia Therapeutics common stock at a price of $9.21 per share. According to the filing, this was a mandatory “sell-to-cover” transaction to satisfy his tax withholding obligation from restricted stock units that vested on January 1, 2026, and it is explicitly described as not a voluntary trade. After this transaction, he beneficially owned 101,528 shares of Intellia common stock directly.

Insider Trade Summary

Net Seller: 10,397 shares ($95,756)

Net Sell 1 txn

Insider BASTA JAMES

Role EVP, General Counsel

Sold 10,397 shs ($96K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,397	$9.21	$96K

Holdings After Transaction: Common Stock — 101,528 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BASTA JAMES

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S(1)		10,397	D	$9.21	101,528	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.

	James Basta	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Intellia Therapeutics (NTLA) report for James Basta?

The company reported that EVP and General Counsel James Basta sold 10,397 shares of Intellia Therapeutics common stock on January 5, 2026.

At what price were the NTLA shares sold in James Basta’s Form 4 filing?

The shares were sold at a price of $9.21 per share, as disclosed in the Form 4.

Was James Basta’s NTLA stock sale a discretionary trade?

No. The filing states it was a mandatory “sell-to-cover” to satisfy his tax withholding obligation upon RSU vesting and does not represent a volitional trade.

How many NTLA shares does James Basta own after this transaction?

After the reported sale, James Basta beneficially owned 101,528 shares of Intellia Therapeutics common stock directly.

What triggered the sell-to-cover transaction reported for NTLA’s James Basta?

The sale was triggered by the vesting of RSUs on January 1, 2026, which created a tax withholding obligation covered by selling shares.

What is James Basta’s role at Intellia Therapeutics (NTLA)?

In the filing, James Basta is identified as an officer of Intellia Therapeutics with the title EVP, General Counsel.